Helix BioPharma (TSE:HBP)
TSX:HBP
Want to see TSE:HBP full AI Analyst Report?
HBP Stock Chart & Stats
C$2.40
-C$0.03(-3.23%)
At close: 4:00 PM EST
C$2.40
-C$0.03(-3.23%)
Day’s Range― - ―
52-Week RangeC$0.84 - C$5.40
Previous CloseN/A
Volume518.00
Average Volume (3M)13.00K
Market Cap
C$120.68M
Enterprise ValueC$124.82M
Total Cash (Recent Filing)C$31.00K
Total Debt (Recent Filing)C$359.00K
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Leverage And Equity BufferLow reported leverage and a meaningful equity base provide a structural cushion against short-term liquidity shocks. For a development-stage biotech, minimal debt reduces interest and covenant pressure, preserving flexibility to fund R&D or seek partnerships without immediate refinancing risk.
R&D-focused Business Model And PipelineA concentrated R&D and asset-management model aligns resources to clinical progress rather than commercial operations, lowering fixed commercial costs. This structure supports scalability via partnerships or licensing, making long-term value more dependent on clinical milestones than costly product launches.
Improving Cash Burn Trend Versus Earlier YearsAn improving cash-burn trajectory indicates tighter expense control or better capital efficiency, which can extend runway without new financing. Sustained improvement in cash management increases the probability of reaching key development inflection points before significant dilution or debt is required.
Bears Say
No Revenue And Persistent Operating LossesThe absence of revenue means operations rely entirely on financing and partners; recurring net losses erode equity over time. Without a commercial product, the firm’s intrinsic sustainability depends on successful clinical outcomes or continual capital raises, increasing execution and funding risk.
Negative Free Cash Flow And Ongoing Cash BurnSustained negative free cash flow creates a structural funding need for operations and trials. Regular reliance on external capital can lead to dilution or debt, constraining strategic options and potentially delaying programs if funding terms deteriorate or markets tighten.
Very Small Workforce Limits Internal CapacityA headcount of seven constrains in-house R&D, regulatory, and operational bandwidth. This raises dependence on external contractors and partners to run trials and manage regulatory tasks, which can increase program timelines, costs, and coordination risk relative to better-resourced peers.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.84 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$120.68M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Nov 04, 2026 which is in 143 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Jun 10, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.947%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---